Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trial

PLoS One. 2020 Dec 2;15(12):e0239888. doi: 10.1371/journal.pone.0239888. eCollection 2020.

Abstract

Background: Human challenge models for enterotoxigenic Escherichia coli (ETEC) facilitate vaccine down-selection. The B7A (O148:H28 CS6+LT+ST+) strain is important for vaccine development. We sought to refine the B7A model by identifying a dose and fasting regimen consistently inducing moderate-severe diarrhea.

Methods: An initial cohort of 28 subjects was randomized (1:1:1:1) to receive B7A following an overnight fast at doses of 108 or 109 colony forming units (cfu) or a 90-minute fast at doses of 109 or 1010 cfu. A second cohort included naïve and rechallenged subjects who had moderate-severe diarrhea and were given the target regimen. Immune responses to important ETEC antigens were assessed.

Results: Among subjects receiving 108 cfu of B7A, overnight fast, or 109 cfu, 90-minute fast, 42.9% (3/7) had moderate-severe diarrhea. Higher attack rates (71.4%; 5/7) occurred in subjects receiving 109 cfu, overnight fast, or 1010 cfu, 90-minute fast. Upon rechallenge with 109 cfu of B7A, overnight fast, 5/11 (45.5%) had moderate-severe diarrhea; the attack rate among concurrently challenge naïve subjects was 57.9% (11/19). Anti-CS6, O148 LPS and LT responses were modest across all groups.

Conclusions: An overnight fast enabled a reduction in the B7A inoculum dose; however, the attack rate was inconsistent and protection upon rechallenge was minimal.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Bacterial / blood
  • Antigens, Bacterial / analysis*
  • Antigens, Bacterial / immunology
  • Bacterial Load
  • Bacterial Toxins / immunology
  • Ciprofloxacin / therapeutic use
  • Diarrhea / etiology*
  • Diarrhea / microbiology
  • Diarrhea / therapy
  • Dose-Response Relationship, Immunologic
  • Enterotoxigenic Escherichia coli / immunology
  • Enterotoxigenic Escherichia coli / isolation & purification
  • Enterotoxigenic Escherichia coli / pathogenicity*
  • Enterotoxins / immunology
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Infections / prevention & control
  • Escherichia coli Proteins / analysis*
  • Escherichia coli Proteins / immunology
  • Escherichia coli Vaccines*
  • Fasting
  • Feces / microbiology
  • Female
  • Fluid Therapy
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Lipopolysaccharides / immunology
  • Male
  • Middle Aged
  • Random Allocation
  • Time Factors
  • Young Adult

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Toxins
  • CS6 antigen, E coli
  • Enterotoxins
  • Escherichia coli Proteins
  • Escherichia coli Vaccines
  • Immunoglobulin G
  • Immunoglobulin M
  • Lipopolysaccharides
  • Ciprofloxacin
  • heat-labile enterotoxin, E coli

Grants and funding

This study was funded by the Congressionally Directed Medical Research Program through the Joint Warfighter Medical Research Program under Contract No. W81XWH-15-C-0083 to the Henry M. Jackson Foundation for the Advancement of Military Medicine. The U.S. Army Medical Research Acquisition Activity was the awarding and administering acquisition office. The study was also funded by a Collaborative Research and Development Agreement with PATH (NCRADA-NMRC-15-9589) and a Clinical Trial agreement between PATH and JHU (GAT.1957-00908740-CTA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.